Targeting Iatrogenic Cushing's Syndrome With 11 β-hydroxysteroid Dehydrogenase Type 1 Inhibition

Condition:   Iatrogenic Cushing's Disease Interventions:   Drug: AZD4017 and prednisolone;   Drug: Placebo Oral Tablet and prednisolone Sponsors:   University of Oxford;   AstraZeneca Not yet recruiting - verified April 2017
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials